Physician profile
Allan Hu
NPI 1992092167
$581.32
in general payments reported to CMS, 2019-2025
16 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.38 · 2021: $147 · 2022: $66.36 · 2023: $51.96 · 2024: $130 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $139.09 | 2021-2023 | |
| Pfizer INC. | $89.43 | 2021-2024 | |
| Novo Nordisk INC | $65.95 | 2024-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $53.39 | 2020-2022 | |
| Abbvie INC. | $39.36 | 2023-2025 | |
| Gilead Sciences, INC. | $32.67 | 2021-2025 | Veklury |
| Exact Sciences Corporation | $22.83 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $19.93 | 2024 | Auvelity |
| Dexcom, INC. | $17.11 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.40 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $15.59 | 2021 | |
| Verona Pharma, INC. | $15.22 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $13.95 | 2025 | Farxiga |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $13.34 | 2024 | Repatha |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13.24 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.